We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genetix Grp | GTX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 84.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 84.00 | 84.00 |
| Top Posts |
|---|
Posted at 15/1/2009 08:36 by darlocst Trading statement out today. Confirms GTX are in line with expectations."Charles de Rohan, Chief Executive of Genetix, commented: "We made further good progress in 2008 despite the wider economic conditions and volatile exchange rate markets. Our strategy of investing in the business to drive top line growth and underlying profitability and earnings per share is bearing fruit and positions us well to deliver sustained shareholder value. "The Group is profitable, financially strong and benefits from a number of defensive qualities. We continue to tightly manage our cost base in line with the current economic trading environment. With world class products and deep customer relationships, the business is well placed and able to meet the opportunities and challenges for the coming year" Market cap = £39.13m Cash = £15.2m EV = £24m In line with market expectations for FY 2008 confirmed, which are: EPS = 6p PBT = £4.76m They will gain further benefit from the weak GBPUSD exchange rate over the coming year & have the possibility of using that large cash pile to make earning enhancing acquisitions. Stripping out the cash puts GTX on a PE of less than 6 for FY2008, which for a company with a large cash pile, growing earnings in a traditionally defensive sector looks good value. I continue to hold. |
Posted at 03/11/2008 16:45 by darlocst I bought some GTX today.No debt, half market cap covered by cash, positive cash flow, sales growth of 20% per year. 44% of earnings in dollars last year so the exchange rate will provide a nice boost going forward. New CEO joined earlier this year bringing a greater sales focus. EPS forecast of 6p for 08, stripping out cash that puts them on a PE of just over 3. With the potential of using the cash pile for acquisitions to boost growth these look attractively priced. |
Posted at 19/4/2007 15:30 by darlocst Anybody still holding these?New product release from Genetix, sounds pretty good. This is exactly the type of product, with value added from new acquisition AIS, that will mean GTX will grow their sales more than the forecast this year. AGM is on May 9th, hopefully an update on trading then. |
Posted at 30/10/2006 19:35 by adam Is there a break fee if GTX decide too much? |
Posted at 20/3/2006 20:21 by tole Genetix "buy," target price raised LONDON, March 1 (newratings.com) - Analyst Jonathan Kwok of Panmure Gordon & (LSE: PMR.L - news) amp; Co maintains his "buy" rating on Genetix Group (LSE: GTX.L - news) (ticker: GTX (NASDAQ: GTXI - news) -GBX). The target price has been raised from 61p to 68p. In a research note published this morning, the analyst mentions that the company has reported its top-line and bottom-line for 2005 ahead of the estimates, primarily due to substantial gross margin expansion, mix shift to high-margin products and an increase in instrumentation sales. Genetix has posted a sequential decline in its R&D and sales & marketing costs and a sequential increase in its interest income for the year. Anyone any thoughts on this one - cash must pretty much underpin the price at this level. |
Posted at 01/3/2006 14:24 by scumdog Decent enough results. However, only 55% of profit before tax is from operations - the remainder is interest received on the £25m cash pile their holding.This company exhibits similar characteristics to Celsis (CEL) which also holds a significant amount of cash. Celsis does pays a (smallish) dividend whereas no mention of dividends in the Genetix statement today. The Celsis share price has traded within a narrow range for 18 months now. The biotech sector doesn't appear popular with investors at present and hasn't been for 2 or 3 years. |
Posted at 29/10/2003 13:30 by mad4it Anyone watching these ? I bought a few at 48p and 60p.This looks like a good potential recovery story to me. A profitable company, with Approx 29p in cash, supplying state of the art equipment to the biotech industry. Recent director purchase of 50k at 55p and it's good to see the options issued to the new COO at 51.5p are performance related. I remember when GTX floated, their products were considered second to none. We are seeing a lot of growth in the biotech areas where they are supplying products and their products are still seen as a must have by the big Pharma companies (see below). Worth a punt I reckon. Here's the most recent, relevant info: 29/07/03: LONDON (AFX) - Genetix Group PLC said sales fell to 4.9 mln stg from 6.3 mln stg in a continuing difficult trading environment. For the six months to June 30, pre-tax profit fell to 0.2 million from 1 mln stg in 2002. It said conditions were challenging throughout the first six months of 2003. Difficulties for the biotechnology sector in raising funds, cutbacks and delays in academic grants, and pressure on pharmaceutical companies to orientate their R&D towards late-stage products have put pressure on supplier companies such as Genetix, it said. But despite these "tough conditions", Genetix remains profitable overall and financially strong with 21.4 mln stg of cash in the bank and an innovative pipeline of new products to generate future revenue, it said. Looking ahead, it said it remains confident in the company's ability to increase its market share as well as the opportunities to enter new markets. But in view of the continuing uncertain trading environment, the company remain cautious about prospects for 2003, although it anticipates maintaining a strong cash position of over 20 mln stg throughout the year. "We are encouraged by recent signs of a return of investor confidence in the biotech sector on the back of promising clinical data and product approvals, which underline the long-term promise of the industry," it said. .................... RNS Number:5130O Genetix Group PLC 11 August 2003 Genetix launches the aliQuot liquid handler Pre-launch orders placed by two of the top three major pharmaceutical companies Boston, USA, 11 August 2003 - Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces the launch of the aliQuot, an automated solution for the low volume dispensing of reagents, chemicals, cells, beads, reaction mixes and other media, at the Drug Discovery Technology conference in Boston, USA. The aliQuot, a desktop machine, uses a proprietary fast pressure-timing dispense mechanism to fill a 1536-well plate with one microlitre in under 30 seconds. The level of accuracy (well-to-well CV of approximately 5%) is unsurpassed by any other instrument in its price bracket. The major markets for this product will be drug discovery, forensics, genetic screening, genomics research and high throughput screening. Low volume dispensing is economically beneficial to pharmaceutical companies when testing compounds with reagents which can cost thousands of dollars per millilitre. Using smaller volumes in these assays enables a greater number of tests to be carried out, or the same number of tests at less cost. Another feature of the aliQuot which reduces the cost of assays is a backfilling function which allows unused compound or reagent remaining in the dispensing pipes to be flushed back into the reservoir bottle for future use. Future developments are likely to include the simultaneous dispensing of up to eight reagents. Julian Burke PhD, Chief Scientific Officer of Genetix, commented: "The aliQuot makes small volume dispensing accessible to laboratories previously unable to conduct assays on this scale because of budget or space constraints, it also offers a more economical solution to those larger companies already conducting tests on this level. Building on skills acquired during the development of the Qfill2 liquid handler, Genetix is able to offer this small volume capability at excellent speed and accuracy to it customers. Multiple pre-launch orders have already been received by two of the three leading pharmaceutical companies." |
Posted at 14/7/2002 13:18 by pfb5 FINMAC - two things spring to mind.(i) there's not much trade in this one, it's a small company with a limited market and not much to shout about. (ii)it's in the wrong sector, by all accounts. Very often labelled as 'pharmaceutical' they actually manufacture machinery which is used in the analysis of DNA and now that the Human Genome Project has finished the gene map, GTX is moving in to equipment for the field of proteomics which is the next stage. Apart from Sept 11th general crash, they announced last October that targets for the year would not be met due to the effects of that catastrophe (see and the price plummetted that day without any significant trades that I could see. Now I'm not an expert at this but it looks to me like the market-makers moved the price, not the market supply & demand. Sales were still up but not as much as anticipated, so profit was down, however note that there was a massive increase in R&D. Interims are due 29th July when we'll see how this year looks, but I don't see much upwards movement being likely as the market is so small - unless the Corporate Broker does some stirring up. I've got a holding which I'm sitting on in the hope of improvement, I don't see any reason to bail out, it just needs a long term view in my opinion. |
Posted at 10/7/2001 08:15 by zzaxx99 'Genetix Group plc (LSE: GTX), the genomics and proteomics technology group, today announces a further expansion of its range of genomic tools with the launch of an effective Clone Library Management System.Following the sequencing of the human genome and genomes from other organisms, many research laboratories are challenged by the number of DNA samples that need to be archived. A small bacterial genome will produce over 100,000 sequences. The Genetix QSelect will allow such a library to be copied in a few hours, a process that usually takes several working days. Furthermore, single samples can be identified and picked for further analysis in a matter of minutes, a dramatic improvement in speed and accuracy. The QSelect is the latest in a range of high precision robots designed to assist the researcher in discovering the function of genes and proteins in the laboratory. Like the MegaPix, launched at the end of 2000, it is a high throughput, highly automated robot which complements Genetix's existing range of products in the area of genomic analysis....' |
Posted at 05/12/2000 23:00 by mj thomson Muchas WongaApologies, it was in fact citywire and not sharecast that tipped GTX. You are much more knowlegable about the genomic sector than myself, hence I don't feel in position to comment on the relative merits of investing in GTX rather than OGM or PRM. But I can comment on SCSW's comments. SCSW are bullish on GTX as firstly they believe the sector is likely to be one of the major winners next year. Secondly they appear to be bullish on GTX in particular because they are a 'small' company, which I believe OGM and PRM are not. Thirdly it makes a profit and has a p/e of around 40, which is not unreasonable given the sector(although this has obviously risen over the past few days). PS Their final comment in the article was "the shares look likely for a warm reception when dealings start on 29/11/00" - certainly true. I hope this helps, Matthew |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
